| Literature DB >> 33836678 |
Ke Chen1, Yu Pan1, Chao-Jie Huang1, Qi-Long Chen1, Ren-Chao Zhang2, Miao-Zun Zhang3, Guan-Yu Wang1, Xian-Fa Wang1, Yi-Ping Mou2, Jia-Fei Yan4.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a leading causes of cancer mortality worldwide. Currently, laparoscopic pancreatic resection (LPR) is extensively applied to treat benign and low-grade diseases related to the pancreas. The viability and safety of LPR for PDAC needs to be understood better. Laparoscopic distal pancreatectomy (LDP) and pancreaticoduodenectomy (LPD) are the two main surgical approaches for PDAC. We performed separate propensity score matching (PSM) analyses to assess the surgical and oncological outcomes of LPR for PDAC by comparing LDP with open distal pancreatectomy (ODP) as well as LPD with open pancreaticoduodenectomy (OPD).Entities:
Keywords: Adenocarcinoma; Laparoscopy; Morbidity; Pancreatectomy; Survival
Year: 2021 PMID: 33836678 PMCID: PMC8034161 DOI: 10.1186/s12885-021-08117-8
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Flow chart of patient selection and literature search strategy
Separate comparison of demographics and clinical characteristics
| Variable | LDP ( | ODP ( | LPD ( | OPD ( | ||
|---|---|---|---|---|---|---|
| Age (years)a | 62.7 ± 8.7 | 62.9 ± 8.8 | 0.90 | 62.4 ± 8.2 | 62.2 ± 8.4 | 0.87 |
| Sex (Male: Female) | 54: 32 | 54: 32 | 1.00 | 67: 34 | 67: 34 | 1.00 |
| BMI (kg/m2)a | 22.5 ± 2.5 | 22.3 ± 2.3 | 0.53 | 22.3 ± 2.5 | 22.5 ± 2.6 | 0.58 |
| ASA classification (I:II:III) | 40: 43: 3 | 41: 42: 3 | 0.99 | 47: 52: 2 | 45: 54: 2 | 0.96 |
| Presence of comorbidity (Yes:No) | 38: 48 | 36: 50 | 0.76 | 44: 57 | 46: 55 | 0.78 |
| Hypertension | 26 | 20 | 22 | 31 | ||
| Diabetes mellitus | 17 | 15 | 15 | 16 | ||
| Cardiovascular | 2 | 1 | 3 | 3 | ||
| Pulmonary | 5 | 4 | 5 | 2 | ||
| Hepatic | 2 | 1 | 3 | 0 | ||
| Others | 1 | 1 | 3 | 2 | ||
| Previous abdominal surgery (%) | 7 (8.1%) | 8 (9.3%) | 0.79 | 6 (5.9%) | 9 (8.9%) | 0.42 |
| Preoperative CA19–9 (IU/mL)b | 108.9 (1.6–3111.0) | 113.2 (4.1–3542.0) | 0.40 | 125.7 (4.4–5041.0) | 145.7 (1.5–5113.0) | 0.95 |
| Preoperative bilirubin (μmol/L)b | 11.8 (4.6–28.3) | 12.5 (5.2–24.3) | 0.74 | 83.5 (4.7–320.8) | 94.0 (5.9–390.8) | 0.44 |
a: values were showed as mean (standard deviation) and tested by Student’s t test; b: values were showed median (range) and tested by Mann-Whitney U test. BMI body mass index, ASA American Society of Anesthesiologists
Separate comparison of surgical data and postoperative outcomes
| Variable | LDP ( | ODP ( | LPD ( | OPD ( | ||
|---|---|---|---|---|---|---|
| Operative time (min)a | 189.1 ± 45.2 | 213.3 ± 54.4 | 416.2 ± 78.8 | 365.0 ± 81.6 | ||
| Estimated blood loss (mL)b | 180 (80–600) | 220 (120–800) | 250 (150–900) | 300 (180–1000) | ||
| RBC transfusion (%) | 3 (3.5%) | 10 (11.6%) | 14 (13.9%) | 22 (21.8%) | 0.14 | |
| Postoperative hospital stay (days)b | 9 (4–34) | 13 (7–42) | 14 (9–69) | 18 (11–52) | ||
| Overall morbidity (n, %) | 8 (9.3%) | 14 (16.3%) | 0.17 | 22 (21.8%) | 32 (31.7%) | 0.11 |
| CR-POPF | 5 | 7 | 12 | 16 | ||
| DGE (Grade A/ Grade B, C) | 0 (0/0) | 3 (2/1) | 6 (4/2) | 10 (5/5) | ||
| PPH (Grade A/ Grade B, C) | 0 (0/0) | 2 (1/1) | 5 (1/4) | 6 (3/3) | ||
| Bile leak | 0 | 0 | 2 | 3 | ||
| Wound infection | 0 | 2 | 1 | 1 | ||
| Lymphorrhea | 1 | 0 | 0 | 2 | ||
| Pulmonary complications | 2 | 2 | 2 | 5 | ||
| Reoperation (%) | 0 | 0 | 1.00 | 6 (5.9%) | 8 (7.9%) | 0.58 |
| Clavien-Dindo classification | 0.33 | 0.42 | ||||
| I-II | 4 (4.7%) | 5 (5.6%) | 10 (9.9%) | 16 (15.8%) | ||
| III-IV | 4 (4.7%) | 9 (10.5%) | 11 (10.9%) | 15 (14.9%) | ||
| V (90-day mortality) | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (1.0%) | ||
| Adjuvant treatment (%) | 61 (70.9%) | 57 (66.3%) | 0.51 | 67 (66.3%) | 65 (64.4%) | 0.77 |
| Time to adjuvant treatment (days)a | 50 (28–82) | 52 (26–88) | 0.14 | 59 (26–98) | 60 (26–103) | 0.68 |
a: values were showed as mean (standard deviation) and tested by Student’s t test; b: values were showed median (range) and tested by Mann-Whitney U test
Comparison of complete LPD and conversion to open procedure
| Variable | Conversion ( | Complete ( | |
|---|---|---|---|
| Age (years) | 64.5 (52–75) | 63 (45–80) | 0.55 |
| Sex (Male: Female) | 5: 5 | 62: 29 | 0.30 |
| BMI (kg/m2) | 24.2 (20.8–28.3) | 21.9 (17.4–27.7) | |
| ASA classification (I:II:III) | 5: 5: 0 | 42: 47: 2 | 0.88 |
| Presence of comorbidity (Yes:No) | 4: 6 | 40: 51 | 0.81 |
| Previous abdominal surgery | 1 (10%) | 5 (5.5%) | 0.47 |
| Preoperative CA19–9 (IU/mL) | 177.5 (40.4–1790.0) | 120.4 (4.4–5041.0) | 0.47 |
| Preoperative bilirubin (μmol/L) | 64.0 (8.3–320.8) | 87.4 (4.7–303.1) | 0.57 |
| Operative time (min) | 455 (320–490) | 400 (270–680) | 0.39 |
| Estimated blood loss (mL) | 550 (200–900) | 240 (150–800) | |
| Postoperative hospital stay (days) | 17.5 (14–38) | 14 (9–69) | |
| Overall morbidity (n, %) | 5 (50%) | 17 (18.7%) | |
| Reoperation (%) | 1 (10%) | 5 (5.5%) | 0.47 |
| Tumor size | 3.5 (1.5–5.0) | 3.0 (1.5–5.4) | 0.56 |
| Radical R0 resection (%) | 8 (80%) | 86 (94.5%) | 0.14 |
| Retrieved lymph node | 20 (16–30) | 22 (13–54) | 0.47 |
| Vascular invasion (%) | 3 (30%) | 14 (15.4%) | 0.37 |
| Perineural invasion (%) | 6 (60%) | 38 (41.8%) | 0.33 |
Note: all continuous data were showed as median (range) and compared by Mann-Whitney U test due to abnormal distribution in conversion group
Separate comparison of pathological examination
| Variable | LDP ( | ODP ( | LPD ( | OPD ( | ||
|---|---|---|---|---|---|---|
| Tumor sizea | 41. ± 1.5 | 4.2 ± 1.4 | 0.97 | 3.0 ± 0.9 | 3.1 ± 1.0 | 0.60 |
| Differentiation | 0.84 | 0.56 | ||||
| Well | 34 | 36 | 33 | 39 | ||
| Moderate | 31 | 27 | 40 | 40 | ||
| Poor | 21 | 23 | 28 | 22 | ||
| Radical R0 resection (%) | 83 (96.5%) | 78 (90.7%) | 0.12 | 94 (93.1%) | 90 (89.1%) | 0.32 |
| Retrieved lymph nodea | 14.4 ± 5.2 | 12.7 ± 5.0 | 22.6 ± 6.5 | 21.0 ± 6.2 | 0.07 | |
| Vascular invasion (%) | 17 (19.8%) | 18 (20.9%) | 0.85 | 17 (16.8%) | 20 (19.8%) | 0.59 |
| Perineural invasion (%) | 41 (47.7%) | 38 (44.2%) | 0.65 | 44 (43.6%) | 45 (44.6%) | 0.89 |
| Pathologic T stage | 0.93 | 0.97 | ||||
| T1 | 3 | 4 | 14 | 15 | ||
| T2 | 44 | 45 | 72 | 72 | ||
| T3 | 39 | 37 | 15 | 14 | ||
| Pathologic N stage | 0.66 | 0.60 | ||||
| N0 | 42 | 46 | 50 | 53 | ||
| N1 | 35 | 29 | 44 | 38 | ||
| N2 | 9 | 11 | 7 | 10 |
a: values were showed as mean (standard deviation) and tested by Student’s t test
Fig. 2Kaplan-Meier survival curves. a Cumulative DFS between LDP and ODP. b Cumulative OS between LDP and ODP. c Cumulative DFS between LPD and OPD. d Cumulative OS between LPD and OPD